Mylan v. Janssen: Federal Circuit Affirms-in-Part in Invega Sustenna Generic Patent Battle
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Mylan, NV v. Janssen Pharmaceuticals, Inc. |
| Case Number | 22-1307 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from District of Columbia |
| Duration | Dec 2021 – Apr 2024 2 years 3 months (825 days) |
| Outcome | Mixed Ruling — Affirmed-in-Part, Vacated & Remanded |
| Patent at Issue | |
| Accused Products | Mylan’s generic version of Invega Sustenna (paliperidone palmitate) |
Case Overview
The Parties
⚖️ Plaintiff
Global generic pharmaceutical manufacturer and aggressive ANDA filer in the Hatch-Waxman litigation ecosystem.
🛡️ Defendant
Subsidiary of Johnson & Johnson, holding substantial IP portfolios in central nervous system therapeutics, including Invega Sustenna.
The Patent at Issue
This closely watched pharmaceutical patent dispute centered on a single U.S. patent covering formulation and dosing innovations for a long-acting injectable antipsychotic. This patent has significant commercial implications for the generic drug market.
- • US9439906B2 — Formulation and dosing of paliperidone palmitate (Invega Sustenna)
The case was brought as an infringement action under Hatch-Waxman, with Mylan’s ANDA filing triggering Janssen’s claims.
Developing a generic drug?
Check if your formulation might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
The Federal Circuit issued a mixed ruling: Affirmed-in-Part and Vacated and Remanded-in-Part, with the appeal also dismissed in part. No specific damages figure was publicly disclosed, consistent with Hatch-Waxman litigation norms where declaratory and injunctive relief—not monetary damages—are the primary remedies at stake. This outcome extends the legal uncertainty around Mylan’s generic Invega Sustenna.
Key Legal Issues
The Federal Circuit’s analysis likely focused on critical elements typical in Hatch-Waxman cases: claim construction, validity challenges (e.g., obviousness under 35 U.S.C. § 103 or enablement under § 112), and infringement findings. The decision to affirm in part suggests some lower court findings were upheld, while the vacatur and remand indicate reversible error, potentially in claim construction or the application of validity standards. This requires fresh analysis at the lower court, delaying final resolution.
The partial dismissal further suggests that some claims or parties did not meet appellate standing or procedural prerequisites. Practitioners should consult the court’s published opinion directly via the Federal Circuit’s official case repository or PACER for complete legal reasoning.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in developing generic pharmaceutical formulations. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View the patent family around Invega Sustenna
- See which companies are most active in long-acting injectables
- Understand claim construction patterns for pharmaceutical formulations
🔍 Check My Generic Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical product.
- Input your drug formulation or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Paliperidone palmitate formulations
Active Litigation
US9439906B2 remains contested
Design-Around Options
Possible for formulation variants
✅ Key Takeaways
Federal Circuit split dispositions in ANDA cases require careful issue preservation at the district court level to maximize appellate options.
Search related case law →Partial dismissals signal the importance of procedural standing analysis before filing appeal.
Explore precedents →Frequently Asked Questions
The case involved U.S. Patent No. US9439906B2, covering formulations related to paliperidone palmitate, the active ingredient in Janssen’s branded antipsychotic injectable Invega Sustenna.
The court issued a split decision—affirming in part, vacating and remanding in part, and dismissing in part—sending certain issues back to the lower court for further proceedings.
The partial remand extends legal uncertainty around Mylan’s ANDA approval pathway. Final resolution depends on the outcome of remand proceedings, which practitioners should monitor via PACER.
Ready to Strengthen Your Pharmaceutical Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States Court of Appeals for the Federal Circuit — Case 22-1307
- U.S. Food & Drug Administration — ANDA Process
- Public Access to Court Electronic Records (PACER)
- Cornell Legal Information Institute — 35 U.S.C. § 271(e)(2)
- Google Patents — US9439906B2
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.